Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14676 - 14700 of 15114 in total
CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … lipid profiles, and this dose has proven to be well tolerated in clinical trials. ... in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and
Experimental
Illicit
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Displaying drugs 14676 - 14700 of 15114 in total